Eris Lifesciences Ltd
NSE:ERIS

Watchlist Manager
Eris Lifesciences Ltd Logo
Eris Lifesciences Ltd
NSE:ERIS
Watchlist
Price: 1 549.2 INR 0.47%
Market Cap: 211B INR

Eris Lifesciences Ltd
Note Receivable

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Eris Lifesciences Ltd
Note Receivable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Note Receivable CAGR 3Y CAGR 5Y CAGR 10Y
Eris Lifesciences Ltd
NSE:ERIS
Note Receivable
₹799.6m
CAGR 3-Years
97%
CAGR 5-Years
84%
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Note Receivable
₹3.7B
CAGR 3-Years
7%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Note Receivable
₹5.4B
CAGR 3-Years
N/A
CAGR 5-Years
59%
CAGR 10-Years
7%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Note Receivable
₹2.6B
CAGR 3-Years
-51%
CAGR 5-Years
-40%
CAGR 10-Years
-21%
Lupin Ltd
NSE:LUPIN
Note Receivable
₹2.3B
CAGR 3-Years
-15%
CAGR 5-Years
10%
CAGR 10-Years
-3%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Note Receivable
₹2.4B
CAGR 3-Years
28%
CAGR 5-Years
25%
CAGR 10-Years
2%
No Stocks Found

Eris Lifesciences Ltd
Glance View

Market Cap
211B INR
Industry
Pharmaceuticals

Nestled in the competitive landscape of India's pharmaceutical sector, Eris Lifesciences Ltd. has carved a niche for itself by focusing intently on the domestic market, predominantly within the specialty prescription segment. Founded in 2007 by Amit Bakshi, the company has distinguished itself with a strategy that emphasizes building relationships with medical professionals through a robust field force, eschewing the conventional tactic of overwhelming physicians with a vast army of generic products. Eris opts for precision, targeting chronic and lifestyle-related ailments such as diabetes, cardiology, and neurology. This focus on long-term therapies aligns with the rising demand for healthcare tailored to the aging population's needs and the increase in lifestyle diseases in India, thus ensuring a steady stream of revenue. The brilliance of Eris Lifesciences' business model is reflected in its comprehensive distribution network and a well-coordinated supply chain that covers a significant portion of Indian urban centers. By manufacturing many of its products in-house, Eris maintains control over production quality and cost – a strategic move that bolsters its pricing power in the competitive generics market. The company also adeptly tweaks its offerings and strategies based on physician feedback and market trends, ensuring relevance and resonance with its target segments. This model is not about flooding the market with a plethora of offerings; it's about precision placement with specialized therapeutic products that meet specific, high-demand needs – a strategy that has consistently translated into tangible financial growth.

ERIS Intrinsic Value
1 358.12 INR
Overvaluation 12%
Intrinsic Value
Price

See Also

What is Eris Lifesciences Ltd's Note Receivable?
Note Receivable
799.6m INR

Based on the financial report for Sep 30, 2025, Eris Lifesciences Ltd's Note Receivable amounts to 799.6m INR.

What is Eris Lifesciences Ltd's Note Receivable growth rate?
Note Receivable CAGR 5Y
84%

Over the last year, the Note Receivable growth was 127%. The average annual Note Receivable growth rates for Eris Lifesciences Ltd have been 97% over the past three years , 84% over the past five years .

Back to Top